Pharmacological management of intermittent claudication: a meta-analysis of randomised trials.
Intermittent claudication, a symptom of atherosclerosis in the large vessels of the lower limbs, greatly affects patient mobility and quality of life. Medical therapy for a moderate form of this condition includes vasodilators, antiplatelet agents and alternative treatments such as ginkgo biloba.A meta-analysis of results from 52 trials (including 5088 patients) was conducted for all current medical therapies for intermittent claudication. After 24 weeks, some of the medical therapies were found to be more effective than placebo for the primary end-points of either pain-free walking distance or maximum walking distance. Vasodilators presented the best results in walking distance. Pentoxifylline offered better results than naftidrofuryl, although the treatment benefit, measured in additional metres walked with treatment than without, was modest. Antiplatelets, ginkgo biloba and levocarnitine were slightly more effective than placebo, although the treatment benefit was of limited clinical importance. On average, patients walked 60m further with therapy than without, and only about half of that added distance was pain-free. Very little consistent information was available for other clinical end-points, such as overall mortality and adverse effects. These data suggest that some of the medical therapy, pentoxifylline in particular, can only modestly increase functional status in patients with moderate intermittent claudication. There is a need for uniformity in research design and reporting of trials. A future trial comparing medical therapy with physical therapy is indicated.
Moher
D
D
Thomas C. Chalmers Centre for Systematic Reviews, CHEO Research Institute, Ottawa, Ontario, Canada. dmoher@uottawa.ca
Pham
B
B
Ausejo
M
M
Saenz
A
A
Hood
S
S
Barber
G G
GG
D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design